ovel therapeutic targets and biomarkers in patients with Systemic Lupus Erythematosus
Withdrawn
- Conditions
- SLEsystemic lupus erythematosus10003816
- Registration Number
- NL-OMON35524
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 62
Inclusion Criteria
Patients full-filling the ACR criteria for systemic lupus erythematosus
Exclusion Criteria
patients with proven other auto-immune disorders
Pregnant women
malignancy
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>to study the expression of IL-7, TSLP, CD30L and their receptors in peripheral<br /><br>blood and urine of patients with SLE as compared to healthy controls. </p><br>
- Secondary Outcome Measures
Name Time Method <p>To study their correlation with disease activity and immunological parameters.<br /><br>And to assess inflammatory mediators present in serum and urine, and those<br /><br>expressed by T-cells and myeloid cells, to identify biomarkers that reflect<br /><br>disease activity and will help to stratify patients with SLE. The results of<br /><br>the proposed studies may contribute to a future treatment strategy by blockade<br /><br>of some of the investigated inflammatory mediators.<br /><br>Third objective: Leucocytes will also be stored for DNA isolation, which will<br /><br>be used for analyses of polymorphic sites that might be involved in regulation<br /><br>of transcription of the investigated mol</p><br>